Methoxyetomidate is an investigational anesthetic agent being developed by Jinzhou Ahon Pharmaceutical Co., Ltd. It is a short-acting intravenous anesthetic that acts as a positive allosteric modulator of GABAA receptors. As of 2024, methoxyetomidate is undergoing Phase 3 clinical trials for use in anesthesia.